Apogee Therapeutics, Inc.APGENASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +12.08% | +8.96% | +15.95% | +3.39% | +3.48% |
| Weighted Average Shares Diluted Growth | +12.08% | +8.96% | +15.95% | +3.39% | +3.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +286.90% | +0.00% | +0.00% | -6.16% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +82.05% | +87.83% | -13.29% | -17.85% | -19.34% |
| Book Value per Share Growth | +60.11% | +73.16% | -27.54% | -22.56% | -22.85% |
| Debt Growth | +0.00% | +481.66% | +567.19% | +165.61% | -18.84% |
| R&D Expense Growth | +167.82% | +108.02% | +61.54% | +67.75% | +18.52% |
| SG&A Expenses Growth | +79.27% | +90.85% | +75.02% | +56.99% | +31.82% |